Scancell Holdings Plc

Scancell Holdings Plc

1.06
USD
-0.09
(-7.83%)
177.50MMarket Cap
Feb 04Next Earn

Scancell Holdings Plc Documents

H2 2025 · Presentation

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ · 31 pages

Read Scancell Holdings Plc's results firsthand

Preview the first 2 pages of this presentation
Create a free account to start reading

Full documents are included with Professional

H2 2025 documents